Today: 8 February 2026
Subscribe
Browse Category

Pharmaceuticals News 2 February 2026 - 4 February 2026

Pfizer (PFE) stock price slips before the bell after obesity-drug update, 2026 outlook

Pfizer (PFE) stock price slips before the bell after obesity-drug update, 2026 outlook

Pfizer shares fell 3.4% to $25.77 in Wednesday’s premarket after Novo Nordisk warned of lower 2026 sales and price pressure in obesity drugs. Pfizer’s GLP-1 trial met its main goal, showing up to 12.3% mean weight loss at 28 weeks, but safety questions remain. The company reaffirmed 2026 guidance and reported $17.6 billion in Q4 revenue. Investors await more VESPER-3 data at the June 6 ADA meeting.
4 February 2026
··
Eli Lilly stock in focus before earnings after Novo warns on obesity-drug price squeeze

Eli Lilly stock in focus before earnings after Novo warns on obesity-drug price squeeze

Eli Lilly shares fell 0.5% to $998.50 in premarket trading Wednesday after a 4% drop Tuesday, following Novo Nordisk’s warning of up to a 13% drop in 2026 sales and profits. Novo cut prices and launched an oral Wegovy, while Lilly plans to cap higher-dose obesity drug prices at $399 per month for repeat cash buyers. Investors await Lilly’s Q4 results and comments on pricing and competition.
4 February 2026
···
Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Novo Nordisk warned adjusted sales and operating profit may fall 5% to 13% in 2026, citing U.S. price cuts and rising competition from Eli Lilly. Shares plunged 18% in early Copenhagen trading. CEO Mike Doustdar called the U.S. price reductions for Wegovy “painful.” Novo also flagged patent expiries and pressure from compounded GLP-1 drugs.
4 February 2026
···
GSK stock swings after earnings as new CEO Luke Miels sets softer 2026 outlook

GSK stock swings after earnings as new CEO Luke Miels sets softer 2026 outlook

GSK shares rose 1.4% Wednesday morning after new CEO Luke Miels issued a 2026 outlook projecting slower sales growth and warning of possible weakness in vaccines and general medicines. The company reported 2025 sales up 7% to £32.67 billion and forecast 2026 turnover growth of 3% to 5%. Investors remain focused on GSK’s ability to manage looming HIV patent expirations.
4 February 2026
···
Johnson & Johnson stock price rises after RBC target hike as investors eye talc risk, new data

Johnson & Johnson stock price rises after RBC target hike as investors eye talc risk, new data

Johnson & Johnson shares rose about 1% Tuesday to $233.10 after RBC Capital Markets raised its price target, citing ongoing talc litigation risk. The company highlighted new real-world data showing ERLEADA cut death risk by 51% in certain prostate cancer patients. Investors await management’s next comments at the TD Cowen conference on March 3.
4 February 2026
··
Merck stock price rises after hours after choppy day — MRK traders focus on 2026 outlook and FDA dates

Merck stock price rises after hours after choppy day — MRK traders focus on 2026 outlook and FDA dates

Merck shares rose 2.2% in after-hours trading Tuesday, closing at $115.84 after the company’s 2026 revenue forecast missed Wall Street estimates. The drugmaker cited a $2.5 billion hit from patent expirations, Medicare price talks, and weaker COVID-19 pill sales. Investors are watching Keytruda demand, Gardasil’s China performance, and FDA decisions expected later in 2026.
4 February 2026
··
Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly shares fell 3.9% to $1,003.46 on Tuesday, tracking a sharp 14% drop in Novo Nordisk after its 2026 forecast signaled deeper pricing pressure in the obesity-drug market. Pfizer also slipped on new weight-loss drug data. Lilly will report quarterly results Wednesday, as investors watch for signs of further price cuts and shifting demand in the sector.
4 February 2026
····
Merck stock rises despite cautious 2026 outlook as patent losses loom

Merck stock rises despite cautious 2026 outlook as patent losses loom

Merck shares rose 3.1% to $116.86 after fourth-quarter earnings beat estimates, with Keytruda sales up 7% to $8.37 billion. The company forecast 2026 sales of $65.5–$67.0 billion, below Wall Street expectations, citing patent expirations and pricing pressure. Gardasil sales fell 34% to $1.03 billion. The FDA accepted Merck’s application for Winrevair, with a decision expected by September 2026.
3 February 2026
··
Novo Nordisk warns 2026 sales could fall — and the Wegovy pill isn’t saving the mood yet

Novo Nordisk warns 2026 sales could fall — and the Wegovy pill isn’t saving the mood yet

Novo Nordisk forecast 2026 adjusted sales and operating profit will fall 5%–13% at constant exchange rates, citing pricing pressure and competition. U.S.-listed shares dropped about 12% after the outlook. The company reported 2025 sales up 10% to 309.1 billion Danish crowns and operating profit up 6%. Early U.S. uptake of its Wegovy pill was noted, but patent expiries and lower realized prices remain concerns.
3 February 2026
·
Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly shares fell 1.4% to $1,029.99 by midday Tuesday as U.S. prices for GLP-1 obesity drugs dropped sharply, prompting analysts to cut long-term forecasts. Novo Nordisk and Pfizer reported strong weight-loss data for rival drugs this week, intensifying competition. Investors await Lilly’s earnings update Wednesday for signals on pricing, demand, and supply outlooks.
3 February 2026
·····
Pfizer stock drops on obesity-drug data and 2026 outlook — what investors watch next

Pfizer stock drops on obesity-drug data and 2026 outlook — what investors watch next

Pfizer shares fell 3.4% to $25.76 early Tuesday after quarterly results and new Phase 2b obesity drug data. The company reported adjusted Q4 earnings of 66 cents per share on $17.56 billion revenue, both above analyst estimates. Pfizer reaffirmed its 2026 outlook and does not plan share buybacks this year. COVID-19 product sales continued to decline sharply.
3 February 2026
··
GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK shares edged up 0.1% to 1,926.5 pence Tuesday, nearing a one-year high ahead of its earnings report due Wednesday. The company is cutting about 350 R&D jobs in the UK and U.S. and recently returned rights to the WVE-006 drug candidate to Wave Life Sciences. Investors await CEO Luke Miels’ first major update and signals on cost controls and R&D priorities.
3 February 2026
····
AbbVie stock gains ahead of earnings; ABBV investors brace for guidance and a $1.3 billion expense

AbbVie stock gains ahead of earnings; ABBV investors brace for guidance and a $1.3 billion expense

New York, February 2, 2026, 16:10 (EST) — After-hours trading AbbVie shares climbed $2.69, or 1.2%, on Monday, settling at $225.70 after hitting a session high of $229.80. AbbVie is set to release full-year and fourth-quarter earnings on Wednesday. Investors will be watching to see if its newer products can step up as Humira’s sales decline amid growing competition from generics. This is crucial now since the stock can’t afford to wander. Investors demand the numbers first, then the outlook — and both need to meet the high expectations already established in large-cap healthcare. Monday’s market moved more quietly, with
2 February 2026
···
1 2 3 4 5 … 34

Stock Market Today

Tower Semiconductor stock jumps again on Nvidia optics tie-up as earnings near

Tower Semiconductor stock jumps again on Nvidia optics tie-up as earnings near

8 February 2026
Tower Semiconductor shares rose 7.7% to $139.04 Friday after announcing a collaboration with Nvidia on AI data-center networking. The stock touched $141 intraday and gained another 1% after hours. Investors await Tower’s Feb. 11 earnings for details on its silicon photonics work. No financial terms or shipment timeline were disclosed.
Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

8 February 2026
Longsys disclosed new guarantees for a 100 million yuan Hong Kong loan and a $9 million Brazil credit line, bringing its total approved guarantee quota to 11 billion yuan and outstanding guarantees to 5.81 billion yuan. The company said all guarantees are for consolidated subsidiaries and within approved limits. Shares closed at 288 yuan Friday, down 1.6%. China inflation and credit data are due this week.
MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

8 February 2026
MACOM shares rose 3.5% to $235.87 Friday after the company reported fiscal Q1 revenue of $271.6 million and raised its full-year data center growth outlook to 35–40%. Fidelity’s FMR LLC disclosed a 10.7% stake, while shareholder Susan Ocampo filed to potentially sell up to 100,000 shares. Stifel raised its price target to $255. MACOM expects to repay $161 million in convertible notes in March.
Go toTop